Page 203 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

MUM1 0=negative, (<40%), 1=positive (>40%), 9=not available
GCB/ non GCB, 9=not available
MYC- BA 0=neg 1=pos
BCL2- BA 0=neg 1=pos
BCL6- BA 0=neg 1=pos
ABC/GCB/ undeterminate, 9=not available
WHO 2008
WHO 2017
7
9 GCB 1 0 9 9 1 1 9 GCB 1 1 9 GCB 1 1 0 GCB 1 0 9 GCB 1 1 9 GCB 1 9
0
0
9 GCB 1 1
9 GCB 1 0
9 GCB 1 0 9 GCB 1 1
9 GCB 1 1 9 9 1 1 0 GCB 1 0 9 GCB 1 1 9 GCB 1 1 9 GCB 1 1 9 GCB 1 0 9 GCB 1 1 0 GCB 1 1 9 GCB 1 1 1 non-GCB 1 0 9 9 1 0
0 GCB 1 9
9 GCB 1 1 1 GCB 1 1
1 non-GCB 0 0 9 GCB 1 1 1 non-GCB 1 0 9 GCB 1 1 9 GCB 1 1 9 GCB 1 0 0 GCB 1 9
9 GCB 1 1 9 GCB 1 9
9 GCB 1 0
1 GCB
1 ABC
1 GCB
1 poor quality 1 9
DLBCL DLBCL DLBCL BCL-U DLBCL
HGBCL,DH/TH HGBCL, DH/TH HGBCL,DH/TH HGBCL, DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH
HGBCL,DH/TH HGBCL, NOS
R-CHOP with lenalidomide in MYC+ LBCL
FISH GEP
Classification
0 9 BCL-U 1 9 DLBCL
0 9 BCL-U
0 GCB dd DLBCL or BCL-U
0 9 DLBCL DLBCL
0 9 dd DLBCL or BCL-U
0 9 DLBCL
HGBCL, DH/TH
HGBCL,DH/TH HGBCL,DH/TH DLBCL HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH DLBCL HGBCL, DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH dd DLBCL or HGBCL, DH/TH dd DLBCL or HGBCL, DH/TH HGBCL,DH/TH HGBCL, DH/TH
HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH DLBCL
dd HGBCL, NOS or HGBCL, DH/ TH HGBCL,DH/TH dd DLBCL or HGBCL, DH/TH DLBCL
0 GCB 0 9
9 GCB 1 GCB 9 9
DLBCL DLBCL DLBCL DLBCL DLBCL DLBCL DLBCL
0 GCB
0 poor quality
0 GCB BCL-U
1 9 1 9 9 9
9 9
0 9 9 9
1 9
1 9
1 9
0 GCB 0 GCB 0 9
9 9
0 GCB 9 9
0 GCB
DLBCL DLBCL DLBCL
DLBCL
DLBCL dd DLBCL or BCL-U DLBCL DLBCL DLBCL DLBCL DLBCL DLBCL BCL-U
DLBCL DLBCL
DLBCL
201